← Patent-cliff monitor small molecule BYSANTI MILSAPERIDONE
Loss of exclusivity May 2044 latest FDA-listed patent expiry
Drug detail Brand name BYSANTI Active ingredient MILSAPERIDONE Strength 10MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval February 2026 Marketing status RX
Listed patents Patent Expires Type 12478619 May 2044 use U-4434 9074254 December 2031 use U-4436 9074256 February 2031 use U-4436 9072742 January 2031 use U-4437 9074255 December 2030 use U-4436 8999638 October 2030 use U-4437 12606869 September 2030 use U-4507 10563259 July 2030 use U-4436 9157121 April 2030 use U-4436 10570453 March 2028 use U-4436
Regulatory exclusivity Code Expires NCE February 2031
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.